BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
“Silence’s area of biotech is moving incredibly quickly. The company could play a big role and I’m delighted to be joining at this time,” he said.
CIMA study reveals qualified management accountants are paid £36,411 more than the typical British workers
Jane Ellison to serve as 'tax minister' following ministerial responsibilities for public health. David Gauke become chief secretary to the Treasury
EY becomes the latest Big Four firm to sign HM Treasury’s Women in Finance Charter
PwC urges for continued progress on gender diversity as government targets FTSE 350 companies to have 33% women on boards by 2020